Menu Search
Equities

Gilead Sciences Inc

GILD:NSQ

Gilead Sciences Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)89.76
  • Today's Change1.13 / 1.27%
  • Shares traded4.06m
  • 1 Year change+20.18%
  • Beta0.1833
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 15-Nov-24
Select bar for recommendation details.
Recommendations15-Nov-24
Buy8
Outperform11
Hold15
Sell0
Strong Sell0

Share price forecast in USD

The 29 analysts offering 12 month price targets for Gilead Sciences, Inc. have a median target of 97.00, with a high estimate of 125.00 and a low estimate of 69.00. The median estimate represents a 9.44% increase from the last price of 88.63.
High41.0%125.00
Med9.4%97.00
Low-22.1%69.00

Dividends in USD

In 2023, Gilead Sciences Inc reported a dividend of 3.00 USD, which represents a 2.74% increase over last year. The 11 analysts covering the company expect dividends of 3.07 USD for the upcoming fiscal year, an increase of 2.17%.
Div growth (TTM)2.74%
More ▼

Earnings history & estimates in USD

On Nov 06, 2024, Gilead Sciences, Inc. reported 3rd quarter 2024 earnings of 2.02 per share. This result exceeded the 1.55 consensus of the 20 analysts covering the company and under-performed last year's 3rd quarter results by 11.79%.
The next earnings announcement is expected on Feb 04, 2025.
Average growth rate-12.20%
Gilead Sciences, Inc. reported annual 2023 earnings of 6.72 per share on Feb 06, 2024.
Average growth rate+0.48%
More ▼

Revenue history & estimates in USD

Gilead Sciences, Inc. had 3rd quarter 2024 revenues of 7.55bn. This bettered the 7.00bn consensus of the 20 analysts covering the company. This was 18.78% above the prior year's 3rd quarter results.
Average growth rate+1.85%
Gilead Sciences, Inc. had revenues for the full year 2023 of 27.12bn. This was 0.60% below the prior year's results.
Average growth rate+4.97%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.